hyperhomocysteinemia

From Aaushi
Jump to navigation Jump to search

Etiology

* homozygous state results in homocystinuria

# cofactor in parenthesis

Epidemiology

Pathology

Laboratory

* see screening for hyperhomocysteinemia

Management

More general terms

Additional terms

References

  1. Stein JH and McBride PE Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. Arch Int Med 158:1301 1998 PMID: https://www.ncbi.nlm.nih.gov/pubmed/9645823
  2. 2.0 2.1 Medical Knowledge Self Assessment Program (MKSAP) 11, 17. American College of Physicians, Philadelphia 1998, 2015
  3. Harrison's Principles of Internal Medicine, 14th ed. Fauci et al (eds), McGraw-Hill Inc. NY, 1998, pg 2199
  4. 4.0 4.1 Journal Watch 22(1):2, 2002 Brown BG et al Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 345:1583, 2001 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11757504
  5. 5.0 5.1 Journal Watch 22(7):56-57, 2002 Seshadri S et al Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 346:476, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/11844848
  6. 6.0 6.1 Journal Watch 22(24):181, 2002 Homocysteine Studies Collaboration Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288:2015, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12387654
    Klerk M et al MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 288:2023, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12387655
    Wilson PW Homocysteine and coronary heart disease: how great is the hazard? JAMA 288:2042, 2002 PMID: https://www.ncbi.nlm.nih.gov/pubmed/12387658
  7. 7.0 7.1 Journal Watch 24(12):94, 2004 a) van Meurs JB et al Homocysteine levels and the risk of osteoporotic fracture. N Engl J Med. 2004 May 13;350(20):2033-41. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15141041
    McLean RR et al Homocysteine as a predictive factor for hip fracture in older persons. N Engl J Med. 2004 May 13;350(20):2042-9. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15141042
    Raisz LG Homocysteine and osteoporotic fractures--culprit or bystander? N Engl J Med. 2004 May 13;350(20):2089-90. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15141048
  8. 8.0 8.1 Lange H, Suryapranata H, De Luca G, Borner C, Dille J, Kallmayer K, Pasalary MN, Scherer E, Dambrink JH. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med. 2004 Jun 24;350(26):2673-81. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15215483
  9. 9.0 9.1 Prescriber's Letter 12(9): 2005 High-dose B vitamins and Heart disease Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=211108&pb=PRL (subscription needed) http://www.prescribersletter.com
  10. 10.0 10.1 Sato Y, Iwamoto J, Kanoko T, Satoh K Homocysteine as a predictive factor for hip fractures in elderly women with Parkinson's disease American Journal of Medicine 118:1250, 2005
  11. 11.0 11.1 McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI, Williams SM. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006 Jun 29;354(26):2764-72. PMID: https://www.ncbi.nlm.nih.gov/pubmed/16807413
  12. 12.0 12.1 Durga J et al, Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007 Jan 20;369(9557):208-16. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17240287
  13. 13.0 13.1 Ray JG et al, Homocysteine-lowering therapy and risk for venous thromboembolism: A randomized trial. Ann Intern Med 2007, 246:761 PMID: https://www.ncbi.nlm.nih.gov/pubmed/17470822
  14. 14.0 14.1 Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM; Veterans Affairs Site Investigators. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA. 2007 Sep 12;298(10):1163-70. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17848650
    Baigent C, Clarke R. B vitamins for the prevention of vascular disease: insufficient evidence to justify treatment. JAMA. 2007 Sep 12;298(10):1212-4. No abstract available. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17848657
  15. 15.0 15.1 15.2 Albert CM et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: A randomized trial. JAMA 2008 May 7; 299:2027 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18460663
  16. 16.0 16.1 House AA et al Effect of B-Vitamin Therapy on Progression of Diabetic Nephropathy JAMA. 2010;303(16):1603-1609. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/20424250 <Internet> http://jama.ama-assn.org/cgi/content/full/303/16/1603
  17. Jardine MJ et al The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis BMJ 2012;344:e3533 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22695899 <Internet> http://www.bmj.com/content/344/bmj.e3533
    Haynes R and Clarke R Homocysteine, the kidney, and vascular disease BMJ 2012;344:e3925 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/22695904 <Internet> http://www.bmj.com/content/344/bmj.e3925
  18. Ray JG. Hyperhomocysteinemia: no longer a consideration in the management of venous thromboembolism. Curr Opin Pulm Med. 2008 Sep;14(5):369-73 PMID: https://www.ncbi.nlm.nih.gov/pubmed/18664964
  19. Gatt A, Makris M. Hyperhomocysteinemia and venous thrombosis. Semin Hematol. 2007 Apr;44(2):70-6. PMID: https://www.ncbi.nlm.nih.gov/pubmed/17433898

Database